弥漫大B细胞淋巴瘤随机对照试验入排标准30年演变
Eligibility criteria for randomised control trials (RCT) in diffuse large B-cell lymphoma (DLBCL) may be becoming increasingly strict. In this analysis, 42 first-line phase III RCTs enrolling DLBCL patients since 1990 were identified from PubMed and clinicaltrials.gov.…
要点
- DLBCL一线III期RCT入排标准30年来显著增多且更严格
- 现代研究标准下仅不足50%真实世界患者符合入组
- 入组标准收紧可能影响近期试验结果的普适性及在研研究招募
核心结论
- 过去三十年一线DLBCL III期RCT入排标准日益严格,可入组患者比例下降,现代研究不足50%患者符合。
研究设计与样本
- 从PubMed和clinicaltrials.gov识别1990年以来42项一线DLBCL III期RCT,按三个预设时期评估31项入排标准变化。
- 将各试验入排标准应用于2010-2020年机构数据库215例连续患者,计算假设可入组比例。
主要发现
- 215例患者中位57%(IQR 47-70)假设符合试验入组。
临床怎么用
- 解读近期DLBCL III期RCT结果时需考虑入排标准严格化对普适性的影响。
- 设计在研研究时需评估标准收紧对招募和真实世界代表性的潜在限制。
局限性
- 可入组比例基于单一机构2010-2020年连续患者数据库的假设应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eligibility criteria for randomised control trials (RCT) in diffuse large B-cell lymphoma (DLBCL) may be becoming increasingly strict. In this analysis, 42 first-line phase III RCTs enrolling DLBCL patients since 1990 were identified from PubMed and clinicaltrials.gov. Changes in 31 individual eligibility criteria were assessed using three pre-defined eras [(1) 1993-2005; (2) 2006-2013; and (3) 2014-2020]. The presence of 15/31 criteria increased significantly over time, and the total number of criteria per study also increased over time [median Era 1: 14·5, interquartile range (IQR) 12·6-16·4; Era 2: 21, 18·8-23·3; Era 3: 23, 21-25; P < 0·001]. When each trial's eligibility criteria were applied to 215 consecutive patients from an institutional database treated between 2010 and 2020, a median of 57% (IQR 47-70) of patients were hypothetically eligible for trial enrolment. The median percentage of patients eligible was 68% (56-91), 54% (37-81) and 47% (38-82) for Era 1, 2 and 3 respectively (P = 0·004). Phase III front-line DLBCL trial criteria have become increasingly restrictive over the last three decades, resulting in a diminishing proportion of trial-eligible patients, with less than 50% of our patients eligible for modern-era studies. This potentially impacts generalisability of recent trial results and will likely limit recruitment to ongoing studies.
引用
- Loh Z, Salvaris R, Chong G, et al. Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years. Br J Haematol. 2021. PMID: 33851428. doi:10.1111/bjh.17436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。